hongweiiewgn personal page - To The Moon

hongweiiewgn

hongweiiewgn

No personal profile

17Follow

6Followers

0Topic

0Badge

2021-06-30

Comment

This Hot Reddit Stock Just Gave Investors an Ominous Warning

2021-06-25

Comment

AMC stock set to snap 4-week win streak

2021-06-18

Nice

Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma

2021-06-18

Comment

Is Tattooed Chef the Next Beyond Meat? 3 Points to Consider

2021-06-24

Comment

This Bull Is Far From Over: 3 Undervalued Blue Chip Dividend Buys

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582358356914075","uuid":"3582358356914075","gmtCreate":1619265631468,"gmtModify":1623757365701,"name":"hongweiiewgn","pinyin":"hongweiiewgn","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/2f1848f0d6e2963f698914aeff51448e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":17,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.33%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":8,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":153237905,"gmtCreate":1625026644707,"gmtModify":1703850446664,"author":{"id":"3582358356914075","authorId":"3582358356914075","name":"hongweiiewgn","avatar":"https://static.tigerbbs.com/2f1848f0d6e2963f698914aeff51448e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582358356914075","authorIdStr":"3582358356914075"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/153237905","repostId":"2147585034","repostType":4,"repost":{"id":"2147585034","pubTimestamp":1625024760,"share":"https://ttm.financial/m/news/2147585034?lang=&edition=fundamental","pubTime":"2021-06-30 11:46","market":"us","language":"en","title":"This Hot Reddit Stock Just Gave Investors an Ominous Warning","url":"https://stock-news.laohu8.com/highlight/detail?id=2147585034","media":"Motley Fool","summary":"It's a warning that investors should take seriously.","content":"<p>This year was shaping up to be a miserable <a href=\"https://laohu8.com/S/AONE\">one</a> for&nbsp;<b>Clover Health</b> (NASDAQ:CLOV). Note the use of the past tense in that statement, though. Thanks in large part to Reddit users piling on, Clover's shares have soared in recent weeks.</p>\n<p>Don't think that the waters are safe to jump aboard the bandwagon for Clover Health yet, however.&nbsp;Here's why this hot Reddit stock just gave investors an ominous warning.</p>\n<h2>Brutal honesty</h2>\n<p>All publicly traded companies want investors to buy their shares. Buying tends to beget more buying, which pushes the stock price up. It's rare that any company warns investors not to buy its stock. But that's exactly what Clover Health did recently.</p>\n<p>Companies that plan to issue additional shares file a prospectus with the U.S. Securities and Exchange Commission (SEC). This prospectus gives potential investors a lot of information about the business and lays out the key reasons why they might want to buy the new shares.</p>\n<p>Clover Health filed such a prospectus earlier this year, outlining its intent to issue additional Class B shares. These shares don't have the same level of voting rights as its Class A shares. Last week, the company submitted an amendment to the SEC for this prospectus. And that amendment contained a brutally honest message for potential investors.</p>\n<p>The company acknowledged that its recent gains could be due to a short squeeze. Because of the potential for an additional short squeeze and its aftermath, Clover Health gave an unusually stark warning to investors: \"Under the circumstances, we caution you against investing in our Class B common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.\" It also noted, \"Investors that purchase shares of our Class A common stock during a short squeeze may lose a significant portion of their investment.\"</p>\n<h2>No fear?</h2>\n<p>Clover Health explained clearly what could happen with both its Class A and Class B shares. The company stated that if another short squeeze happens, once short-sellers cover their positions or if investors otherwise think the short squeeze has run its course, its stock price could fall quickly.</p>\n<p>You might think that such an ominous warning would scare off many investors. Nope. Instead, it produced an opposite effect. Last week, shares of Clover Health soared by a double-digit percentage immediately after the company's amended prospectus with the serious warning was submitted to the SEC.</p>\n<p>This reaction might seem counterintuitive. After all, Clover Health informed investors in no uncertain terms about the risks they face with buying the stock. So why did the shares of the company surge instead of sink? I think there are different reasons for different investors.</p>\n<p>Some truly believe in Clover Health and are willing to hold onto the stock regardless of what happens over the short term. Others are fully aware that the gains generated by a short squeeze could evaporate quickly but think they'll be able to sell in time to still make a big profit. Unfortunately, there could also be some who are new to investing and didn't pay attention to or didn't understand Clover Health's cautionary message.</p>\n<h2>Business vs. stock</h2>\n<p>It's always wise to think of buying a stock as buying a part of a business. That's exactly what you're doing when you buy shares of Clover Health or any other company. When the underlying business is strong and has great prospects, you don't have to be concerned about short-term volatility with the share price.</p>\n<p>However, there are times when share prices get way out of alignment with the prospects of the underlying business. Short squeezes can often make this happen. In these cases, it's especially important to be careful in buying a stock. Sure, you're still buying a part of a business -- but you can pay a lot more than the business is actually worth.</p>\n<p>In my view, there are several reasons to like Clover Health's underlying business. The company has an intriguing technology that physicians use. It's expanding into the original Medicare market, a move that could boost sales tremendously. Clover Health has a visionary management team.</p>\n<p>But buying a stock that's a short squeeze candidate is risky if you aren't ready, willing, and able to sell shares immediately once the short squeeze ends. When a company issues a warning like Clover Health just did, the smart thing to do is to listen and take that warning seriously.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Hot Reddit Stock Just Gave Investors an Ominous Warning</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Hot Reddit Stock Just Gave Investors an Ominous Warning\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/29/this-hot-reddit-stock-just-gave-investors-an-omino/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This year was shaping up to be a miserable one for Clover Health (NASDAQ:CLOV). Note the use of the past tense in that statement, though. Thanks in large part to Reddit users piling on, Clover's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/29/this-hot-reddit-stock-just-gave-investors-an-omino/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://www.fool.com/investing/2021/06/29/this-hot-reddit-stock-just-gave-investors-an-omino/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147585034","content_text":"This year was shaping up to be a miserable one for Clover Health (NASDAQ:CLOV). Note the use of the past tense in that statement, though. Thanks in large part to Reddit users piling on, Clover's shares have soared in recent weeks.\nDon't think that the waters are safe to jump aboard the bandwagon for Clover Health yet, however. Here's why this hot Reddit stock just gave investors an ominous warning.\nBrutal honesty\nAll publicly traded companies want investors to buy their shares. Buying tends to beget more buying, which pushes the stock price up. It's rare that any company warns investors not to buy its stock. But that's exactly what Clover Health did recently.\nCompanies that plan to issue additional shares file a prospectus with the U.S. Securities and Exchange Commission (SEC). This prospectus gives potential investors a lot of information about the business and lays out the key reasons why they might want to buy the new shares.\nClover Health filed such a prospectus earlier this year, outlining its intent to issue additional Class B shares. These shares don't have the same level of voting rights as its Class A shares. Last week, the company submitted an amendment to the SEC for this prospectus. And that amendment contained a brutally honest message for potential investors.\nThe company acknowledged that its recent gains could be due to a short squeeze. Because of the potential for an additional short squeeze and its aftermath, Clover Health gave an unusually stark warning to investors: \"Under the circumstances, we caution you against investing in our Class B common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.\" It also noted, \"Investors that purchase shares of our Class A common stock during a short squeeze may lose a significant portion of their investment.\"\nNo fear?\nClover Health explained clearly what could happen with both its Class A and Class B shares. The company stated that if another short squeeze happens, once short-sellers cover their positions or if investors otherwise think the short squeeze has run its course, its stock price could fall quickly.\nYou might think that such an ominous warning would scare off many investors. Nope. Instead, it produced an opposite effect. Last week, shares of Clover Health soared by a double-digit percentage immediately after the company's amended prospectus with the serious warning was submitted to the SEC.\nThis reaction might seem counterintuitive. After all, Clover Health informed investors in no uncertain terms about the risks they face with buying the stock. So why did the shares of the company surge instead of sink? I think there are different reasons for different investors.\nSome truly believe in Clover Health and are willing to hold onto the stock regardless of what happens over the short term. Others are fully aware that the gains generated by a short squeeze could evaporate quickly but think they'll be able to sell in time to still make a big profit. Unfortunately, there could also be some who are new to investing and didn't pay attention to or didn't understand Clover Health's cautionary message.\nBusiness vs. stock\nIt's always wise to think of buying a stock as buying a part of a business. That's exactly what you're doing when you buy shares of Clover Health or any other company. When the underlying business is strong and has great prospects, you don't have to be concerned about short-term volatility with the share price.\nHowever, there are times when share prices get way out of alignment with the prospects of the underlying business. Short squeezes can often make this happen. In these cases, it's especially important to be careful in buying a stock. Sure, you're still buying a part of a business -- but you can pay a lot more than the business is actually worth.\nIn my view, there are several reasons to like Clover Health's underlying business. The company has an intriguing technology that physicians use. It's expanding into the original Medicare market, a move that could boost sales tremendously. Clover Health has a visionary management team.\nBut buying a stock that's a short squeeze candidate is risky if you aren't ready, willing, and able to sell shares immediately once the short squeeze ends. When a company issues a warning like Clover Health just did, the smart thing to do is to listen and take that warning seriously.","news_type":1},"isVote":1,"tweetType":1,"viewCount":951,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122594155,"gmtCreate":1624627000477,"gmtModify":1703842055198,"author":{"id":"3582358356914075","authorId":"3582358356914075","name":"hongweiiewgn","avatar":"https://static.tigerbbs.com/2f1848f0d6e2963f698914aeff51448e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582358356914075","authorIdStr":"3582358356914075"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/122594155","repostId":"1101793896","repostType":2,"repost":{"id":"1101793896","pubTimestamp":1624624097,"share":"https://ttm.financial/m/news/1101793896?lang=&edition=fundamental","pubTime":"2021-06-25 20:28","market":"us","language":"en","title":"AMC stock set to snap 4-week win streak","url":"https://stock-news.laohu8.com/highlight/detail?id=1101793896","media":"MarketWatch","summary":"Shares of AMC Entertainment Holdings Inc.AMC,-2.74%fell 2.5% in premarket trading Friday, which puts","content":"<p>Shares of AMC Entertainment Holdings Inc.AMC,-2.74%fell 2.5% in premarket trading Friday, which putsthe meme stockon track to snap a four-week win streak in which it rocketed nearly fivefold. </p>\n<p>The movie theater chain's stock has lost 4.3% so far this week, after soaring 390.6% over the previous four weeks. During the weekly win streak, the stock had closed at a record $62.55 on June 2. </p>\n<p>Among&nbsp;other meme stocks, GameStop Corp.GME,-3.21%rose 1.1% in premarket trading Friday, which would put it on track to snap a two-week losing streak in which it shed 13.9%. GameStop shares have slipped 0.7% week-to-date through Thursday. </p>\n<p>Separately, the S&amp;P 500SPX,+0.58%has fallen 0.7% week to date, putting it on track for a third-straight weekly decline.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC stock set to snap 4-week win streak</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC stock set to snap 4-week win streak\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 20:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/amc-stock-set-to-snap-4-week-win-streak-2021-06-25?siteid=rss&utm_campaign=Feed%3A+marketwatch%2Fmarketpulse+%28MarketWatch.com+-+MarketPulse%29&utm_medium=feed&utm_source=feedburner><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of AMC Entertainment Holdings Inc.AMC,-2.74%fell 2.5% in premarket trading Friday, which putsthe meme stockon track to snap a four-week win streak in which it rocketed nearly fivefold. \nThe ...</p>\n\n<a href=\"https://www.marketwatch.com/story/amc-stock-set-to-snap-4-week-win-streak-2021-06-25?siteid=rss&utm_campaign=Feed%3A+marketwatch%2Fmarketpulse+%28MarketWatch.com+-+MarketPulse%29&utm_medium=feed&utm_source=feedburner\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.marketwatch.com/story/amc-stock-set-to-snap-4-week-win-streak-2021-06-25?siteid=rss&utm_campaign=Feed%3A+marketwatch%2Fmarketpulse+%28MarketWatch.com+-+MarketPulse%29&utm_medium=feed&utm_source=feedburner","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101793896","content_text":"Shares of AMC Entertainment Holdings Inc.AMC,-2.74%fell 2.5% in premarket trading Friday, which putsthe meme stockon track to snap a four-week win streak in which it rocketed nearly fivefold. \nThe movie theater chain's stock has lost 4.3% so far this week, after soaring 390.6% over the previous four weeks. During the weekly win streak, the stock had closed at a record $62.55 on June 2. \nAmong other meme stocks, GameStop Corp.GME,-3.21%rose 1.1% in premarket trading Friday, which would put it on track to snap a two-week losing streak in which it shed 13.9%. GameStop shares have slipped 0.7% week-to-date through Thursday. \nSeparately, the S&P 500SPX,+0.58%has fallen 0.7% week to date, putting it on track for a third-straight weekly decline.","news_type":1},"isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128808033,"gmtCreate":1624508774722,"gmtModify":1703838772002,"author":{"id":"3582358356914075","authorId":"3582358356914075","name":"hongweiiewgn","avatar":"https://static.tigerbbs.com/2f1848f0d6e2963f698914aeff51448e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582358356914075","authorIdStr":"3582358356914075"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128808033","repostId":"1182818110","repostType":4,"repost":{"id":"1182818110","pubTimestamp":1624504323,"share":"https://ttm.financial/m/news/1182818110?lang=&edition=fundamental","pubTime":"2021-06-24 11:12","market":"us","language":"en","title":"This Bull Is Far From Over: 3 Undervalued Blue Chip Dividend Buys","url":"https://stock-news.laohu8.com/highlight/detail?id=1182818110","media":"seekingalpha","summary":"Summary\n\nThe Fed jolted investors last week, before Powell backpedalled to reassure everyone.\nThis s","content":"<p><b>Summary</b></p>\n<ul>\n <li>The Fed jolted investors last week, before Powell backpedalled to reassure everyone.</li>\n <li>This shows just how difficult it will be for the Fed to actually rein in the economy.</li>\n <li>Some value names are once again on our \"buy list\". Here are three great ones.</li>\n</ul>\n<p><b>Introduction</b></p>\n<p>On a recent Bloomberg video call, Ray Dalio suggested that the Fed will have a lot of trouble doing any rate hike without having significantly adverse effects on stocks.</p>\n<p>Following the Fed meeting last week, the news that rates might be raised in two years rather than three gave the markets a jolt, as the message was interpreted as hawkish by the investing community.</p>\n<p>This caused Jerome Powell to backpedal, reminding everyone of his favorite word: \"transitory\". It was important that he once again reminded everyone that inflation would head back to 2%, and that nobody needs to worry.</p>\n<p>He did cover his 6 however,stating:</p>\n<blockquote>\n <i>We have to be very humble about our ability to really try to draw a signal out of it [...] It might take some patience to really see what’s happening.</i>\n</blockquote>\n<blockquote>\n Larry Summers had adifferent take on it: \n <i>I don't think the arithmetic is terribly difficult.</i>\n</blockquote>\n<blockquote>\n <i> You're looking at an average GDP gap deficit to potential GDP of 2%, and we're looking at a 14% of GDP fiscal stimulus. [...] The important question is whether there is 6 points of transitory inflation or 2 points of transitory inflation.</i>\n</blockquote>\n<p>This idea is very important. Rather than asking whether inflation is transitory or not, we should be asking how much of it is transitory.</p>\n<p>And this is where the risk currently lies. While the S&amp;P 500 (SPY) performed a roundtrip from 4250 to 4250 with a 90 point drop in between, a lot of the more cyclical stocks took a hit which put them back in our \"Buy List\".</p>\n<p>Our take is that the Fed is realizing that it can't really increase rates without causing ruckus in markets.</p>\n<p>When you add this to the fact that they might not have any choice but to keep printing money to buy bonds as the supply of bonds might overshoot the demand of these from foreign countries who already hold lots of US debt and show limited interest in purchasing the debt at negative real interest rates. This is according to Ray Dalio in the same call with Larry Summers mentioned above.</p>\n<p>The risk of monetary inflation is very real. The likelihood of demand to continue increasing dramatically as money stored in financial markets hits the economy is also very high.</p>\n<p>What we've learned in investing, is that investors are too eager to wrap up a trade and move on to the \"next thing\". Many times, this is shortsighted, as even when the train has left the station, there is a lot of track left ahead.</p>\n<p>This is one of these situations.</p>\n<p>Valuations in high quality blue chips which are sensitive to the economy reopening are still so far from pre-Covid levels.</p>\n<p>The fact that they are taking a breather doesn't detract from their ultimate destination, which is a lot higher.</p>\n<p>In this article I highlight 3 such stocks.</p>\n<p>Plus in the meantime you get to sleep well at night, knowing that they offer a great combination of dividend yield and dividend growth.</p>\n<p>Heads you win, tails you win more.</p>\n<p><b>IBM (IBM)</b></p>\n<p>While IBM has increased from our latest mention of it in a public article, when we were purchasing the stock at a 5%+ yield, it still hovers just below our target \"Buy Below\" price of $150, courtesy of a small pull back last week.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1a8abbcb78d88ebe9b82eb258078cd4c\" tg-width=\"640\" tg-height=\"297\" referrerpolicy=\"no-referrer\"><span>Source: Dividend Freedom Tribe.</span></p>\n<p>Dividend growth has come to a stand still, and while we loaded up lower, it is still a great opportunity.</p>\n<p>The real value lies in the fact that investors are not pricing Krishna's operational excellence since taking over.</p>\n<p>IBM stunned investors with its Q1 results. Fellow author Virginia Backaitis states in her excellent articleanalyzing IBM'soperations:</p>\n<blockquote>\n <i>I like how Krishna is thinking, and I like former Red Hat CEO Jim Whitehurst at his side. They are making purchases that align with IBM's strategy which hasn't always been the case at the company. The product lines that IBM is selling off now are smart choices... and they have others left to sell (but maybe there isn't a buyer).</i>\n</blockquote>\n<p>This value will likely be realized following the spin-off of the legacy business into an entity which will benamed kyndryl.</p>\n<p>Investors will likely be left with a high yield managed infrastructure business, and a low yield high growth cloud stock.</p>\n<p>When it happens, we'll decide which of both we'll hold onto, but we're quite confident that the two pieces will be worth than the sum of the part.</p>\n<p>And while you wait for this, you still get paid 4.5% by a super safe Blue Chip stock, which has the pricing power to fight inflation.</p>\n<p><b>KeyCorp (KEY)</b></p>\n<p>One thing the last round of stress tests showed, was that US banks are resilient, and well capitalized. Yet last week they took a hit after the fed meeting. This week stress tests will be released, and most large banks are expected to do really well.</p>\n<p>After that, dividend increases will come in July as banks are eager to start returning wealth to shareholders.</p>\n<p>Keycorp is no exception. For an analysis of KEY's earnings development you can read Sheen Bay Research'sarticleon the stock.</p>\n<p>Where I differ from his opinion is on the question of the dividend. While he doesn't expect a dividend hike, I expect all major banks to compete in their dividend increases.</p>\n<p>What investors must not forget is that in 2008 KEY paid a dividend of $0.38 per quarter, or double the current dividend.</p>\n<p>Since then, the company has been slowly redeeming itself, increasing the dividend every year.</p>\n<p>The pandemic restrictions stopped KEY in their tracks.</p>\n<p>A look at our MAD Chart shows how eager the bank was at returning capital to shareholders in the past 10 years. Each time the dividend increases, the inferred value ranges shown on the MAD chart goes up.</p>\n<p>In the past 10 years the dividend grew at 20% per annum, the rate dropped to 15% in the past 5 years, hindered by 0 growth last year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ce032ffe59e73db2d6a1e09b4ff723b4\" tg-width=\"640\" tg-height=\"298\" referrerpolicy=\"no-referrer\"><span>Source: Dividend Freedom Tribe.</span></p>\n<p>I believe that a 10-15% increase is very likely this year.</p>\n<p>In this event, KEY's current yield of 3.6% would effectively become a 4% yield.</p>\n<p>But to get fantastic income from KEY, you don't even need that much growth.</p>\n<p>At a 3.6% yield, if you can get 7.5% annual dividend growth you get a fantastic income opportunity.</p>\n<p>Let's look at a simulation.</p>\n<p>Let's suggest a $10K investment in KEY, with dividends reinvested and dividend growth of 7.5% per annum.</p>\n<p>In year 10, you'd expect $1,004 of income, or 10% of your original investment, which is our threshold for a \"great\" income opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/96c24e62697eb475528e1b9f04686a12\" tg-width=\"615\" tg-height=\"240\" referrerpolicy=\"no-referrer\"><span>Source: Dividend Freedom Tribe.</span></p>\n<p>In our mind there is no way that KEY doesn't grow at this rate, which would suggest hitting its pre 2008 dividend in 10 years.</p>\n<p>As such we believe KEY to be a great pick for income investors. As KEY's dividend growth is on the back of growth in earnings and tangible book value per share, there is no doubt in our mind that sooner or later, the price will catch up with the higher income. The fed stress tests might be the catalyst banks need to move higher.</p>\n<p>In the meantime get paid to wait.</p>\n<p><b>Chevron (CVX)</b></p>\n<p>Chevron is another stock which is hovering just below our target \"Buy Below\" price.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/100902df9308eeb7576e22704f403240\" tg-width=\"640\" tg-height=\"298\" referrerpolicy=\"no-referrer\"><span>Source: Dividend Freedom Tribe.</span></p>\n<p>We're surprised that the oil trade is taking so long to play out. In late 2015, early 2016, the recovery to historically normal yields was a lot faster.</p>\n<p>Yet CVX still yields 5%, after proving its resilience, superior balance sheet and increasing the dividend by 4% this year, sustaining their history of higher dividends every year for the past three decades.</p>\n<p>Consider the following slide from their latestearnings call:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b49cefbd9ee55c299d2b3a03211a3b6b\" tg-width=\"640\" tg-height=\"360\" referrerpolicy=\"no-referrer\"><span>Source: Earnings Call.</span></p>\n<p>At $40 brent, the dividend is covered with a little extra debt. As the energy major with the best balance sheet, it can afford this. At $60 brent, there would be excess cash above $25bn, or enough to fund the dividend for two and a half years.</p>\n<p>Brent is currently above $70. The longer it stays above that level, the higher the likelihood that CVX will actually have the excess cash suggested in the latter scenario.</p>\n<p>Back in August last year we suggested that you'll belaughing your wayto the bank with CVX's 6% yield.</p>\n<p>Since then, CVX has marginally beaten the S&amp;P 500, but is far from over.</p>\n<p>In the past 10 years CVX has yielded a median 3.86%. Its forward outlook is arguably better now than it was in much of the past decade, which had the energy market dealing with endemic oversupply. With underinvestment, the opposite is likely to be true in upcoming years.</p>\n<p>If anything CVX should gravitate back towards its median yield which suggests further upside of 20%, much of which we expect will be realized in the latter half of 2021.</p>\n<p>If you simulate a $10K investment in CVX assuming a 5% yield and 4% dividend growth, and reinvest dividends, then in year 10 you'd expect $1,154 in dividends of which $409 is expected to come from dividend reinvestments.</p>\n<p>This equates to 11.54% of the initial investment, making CVX also an excellent income opportunity at current prices.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/53e365890df23b4af31565c7b170c14f\" tg-width=\"615\" tg-height=\"240\" referrerpolicy=\"no-referrer\"><span>Source: Dividend Freedom Tribe.</span></p>\n<p><b>Conclusion</b></p>\n<p>As long term dividend investors, we're always eager to get top companies at great valuations. The fed meeting changed nothing to the reopening trade. If anything it gave them a warning that even the slightest hint of a rate increase would be interpreted as hawkish, which will likely have the consequence of them acting later than they should, which exacerbates the likelihood of the value trade continuing.</p>\n<p>Don't confuse the market taking a breather with the end of the trade.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Bull Is Far From Over: 3 Undervalued Blue Chip Dividend Buys</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Bull Is Far From Over: 3 Undervalued Blue Chip Dividend Buys\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 11:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436276-this-bull-is-far-from-over-3-undervalued-blue-chip-dividend-buys><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nThe Fed jolted investors last week, before Powell backpedalled to reassure everyone.\nThis shows just how difficult it will be for the Fed to actually rein in the economy.\nSome value names are...</p>\n\n<a href=\"https://seekingalpha.com/article/4436276-this-bull-is-far-from-over-3-undervalued-blue-chip-dividend-buys\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVX":"雪佛龙","IBM":"IBM","KEY":"KeyCorp"},"source_url":"https://seekingalpha.com/article/4436276-this-bull-is-far-from-over-3-undervalued-blue-chip-dividend-buys","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1182818110","content_text":"Summary\n\nThe Fed jolted investors last week, before Powell backpedalled to reassure everyone.\nThis shows just how difficult it will be for the Fed to actually rein in the economy.\nSome value names are once again on our \"buy list\". Here are three great ones.\n\nIntroduction\nOn a recent Bloomberg video call, Ray Dalio suggested that the Fed will have a lot of trouble doing any rate hike without having significantly adverse effects on stocks.\nFollowing the Fed meeting last week, the news that rates might be raised in two years rather than three gave the markets a jolt, as the message was interpreted as hawkish by the investing community.\nThis caused Jerome Powell to backpedal, reminding everyone of his favorite word: \"transitory\". It was important that he once again reminded everyone that inflation would head back to 2%, and that nobody needs to worry.\nHe did cover his 6 however,stating:\n\nWe have to be very humble about our ability to really try to draw a signal out of it [...] It might take some patience to really see what’s happening.\n\n\n Larry Summers had adifferent take on it: \n I don't think the arithmetic is terribly difficult.\n\n\n You're looking at an average GDP gap deficit to potential GDP of 2%, and we're looking at a 14% of GDP fiscal stimulus. [...] The important question is whether there is 6 points of transitory inflation or 2 points of transitory inflation.\n\nThis idea is very important. Rather than asking whether inflation is transitory or not, we should be asking how much of it is transitory.\nAnd this is where the risk currently lies. While the S&P 500 (SPY) performed a roundtrip from 4250 to 4250 with a 90 point drop in between, a lot of the more cyclical stocks took a hit which put them back in our \"Buy List\".\nOur take is that the Fed is realizing that it can't really increase rates without causing ruckus in markets.\nWhen you add this to the fact that they might not have any choice but to keep printing money to buy bonds as the supply of bonds might overshoot the demand of these from foreign countries who already hold lots of US debt and show limited interest in purchasing the debt at negative real interest rates. This is according to Ray Dalio in the same call with Larry Summers mentioned above.\nThe risk of monetary inflation is very real. The likelihood of demand to continue increasing dramatically as money stored in financial markets hits the economy is also very high.\nWhat we've learned in investing, is that investors are too eager to wrap up a trade and move on to the \"next thing\". Many times, this is shortsighted, as even when the train has left the station, there is a lot of track left ahead.\nThis is one of these situations.\nValuations in high quality blue chips which are sensitive to the economy reopening are still so far from pre-Covid levels.\nThe fact that they are taking a breather doesn't detract from their ultimate destination, which is a lot higher.\nIn this article I highlight 3 such stocks.\nPlus in the meantime you get to sleep well at night, knowing that they offer a great combination of dividend yield and dividend growth.\nHeads you win, tails you win more.\nIBM (IBM)\nWhile IBM has increased from our latest mention of it in a public article, when we were purchasing the stock at a 5%+ yield, it still hovers just below our target \"Buy Below\" price of $150, courtesy of a small pull back last week.\nSource: Dividend Freedom Tribe.\nDividend growth has come to a stand still, and while we loaded up lower, it is still a great opportunity.\nThe real value lies in the fact that investors are not pricing Krishna's operational excellence since taking over.\nIBM stunned investors with its Q1 results. Fellow author Virginia Backaitis states in her excellent articleanalyzing IBM'soperations:\n\nI like how Krishna is thinking, and I like former Red Hat CEO Jim Whitehurst at his side. They are making purchases that align with IBM's strategy which hasn't always been the case at the company. The product lines that IBM is selling off now are smart choices... and they have others left to sell (but maybe there isn't a buyer).\n\nThis value will likely be realized following the spin-off of the legacy business into an entity which will benamed kyndryl.\nInvestors will likely be left with a high yield managed infrastructure business, and a low yield high growth cloud stock.\nWhen it happens, we'll decide which of both we'll hold onto, but we're quite confident that the two pieces will be worth than the sum of the part.\nAnd while you wait for this, you still get paid 4.5% by a super safe Blue Chip stock, which has the pricing power to fight inflation.\nKeyCorp (KEY)\nOne thing the last round of stress tests showed, was that US banks are resilient, and well capitalized. Yet last week they took a hit after the fed meeting. This week stress tests will be released, and most large banks are expected to do really well.\nAfter that, dividend increases will come in July as banks are eager to start returning wealth to shareholders.\nKeycorp is no exception. For an analysis of KEY's earnings development you can read Sheen Bay Research'sarticleon the stock.\nWhere I differ from his opinion is on the question of the dividend. While he doesn't expect a dividend hike, I expect all major banks to compete in their dividend increases.\nWhat investors must not forget is that in 2008 KEY paid a dividend of $0.38 per quarter, or double the current dividend.\nSince then, the company has been slowly redeeming itself, increasing the dividend every year.\nThe pandemic restrictions stopped KEY in their tracks.\nA look at our MAD Chart shows how eager the bank was at returning capital to shareholders in the past 10 years. Each time the dividend increases, the inferred value ranges shown on the MAD chart goes up.\nIn the past 10 years the dividend grew at 20% per annum, the rate dropped to 15% in the past 5 years, hindered by 0 growth last year.\nSource: Dividend Freedom Tribe.\nI believe that a 10-15% increase is very likely this year.\nIn this event, KEY's current yield of 3.6% would effectively become a 4% yield.\nBut to get fantastic income from KEY, you don't even need that much growth.\nAt a 3.6% yield, if you can get 7.5% annual dividend growth you get a fantastic income opportunity.\nLet's look at a simulation.\nLet's suggest a $10K investment in KEY, with dividends reinvested and dividend growth of 7.5% per annum.\nIn year 10, you'd expect $1,004 of income, or 10% of your original investment, which is our threshold for a \"great\" income opportunity.\nSource: Dividend Freedom Tribe.\nIn our mind there is no way that KEY doesn't grow at this rate, which would suggest hitting its pre 2008 dividend in 10 years.\nAs such we believe KEY to be a great pick for income investors. As KEY's dividend growth is on the back of growth in earnings and tangible book value per share, there is no doubt in our mind that sooner or later, the price will catch up with the higher income. The fed stress tests might be the catalyst banks need to move higher.\nIn the meantime get paid to wait.\nChevron (CVX)\nChevron is another stock which is hovering just below our target \"Buy Below\" price.\nSource: Dividend Freedom Tribe.\nWe're surprised that the oil trade is taking so long to play out. In late 2015, early 2016, the recovery to historically normal yields was a lot faster.\nYet CVX still yields 5%, after proving its resilience, superior balance sheet and increasing the dividend by 4% this year, sustaining their history of higher dividends every year for the past three decades.\nConsider the following slide from their latestearnings call:\nSource: Earnings Call.\nAt $40 brent, the dividend is covered with a little extra debt. As the energy major with the best balance sheet, it can afford this. At $60 brent, there would be excess cash above $25bn, or enough to fund the dividend for two and a half years.\nBrent is currently above $70. The longer it stays above that level, the higher the likelihood that CVX will actually have the excess cash suggested in the latter scenario.\nBack in August last year we suggested that you'll belaughing your wayto the bank with CVX's 6% yield.\nSince then, CVX has marginally beaten the S&P 500, but is far from over.\nIn the past 10 years CVX has yielded a median 3.86%. Its forward outlook is arguably better now than it was in much of the past decade, which had the energy market dealing with endemic oversupply. With underinvestment, the opposite is likely to be true in upcoming years.\nIf anything CVX should gravitate back towards its median yield which suggests further upside of 20%, much of which we expect will be realized in the latter half of 2021.\nIf you simulate a $10K investment in CVX assuming a 5% yield and 4% dividend growth, and reinvest dividends, then in year 10 you'd expect $1,154 in dividends of which $409 is expected to come from dividend reinvestments.\nThis equates to 11.54% of the initial investment, making CVX also an excellent income opportunity at current prices.\nSource: Dividend Freedom Tribe.\nConclusion\nAs long term dividend investors, we're always eager to get top companies at great valuations. The fed meeting changed nothing to the reopening trade. If anything it gave them a warning that even the slightest hint of a rate increase would be interpreted as hawkish, which will likely have the consequence of them acting later than they should, which exacerbates the likelihood of the value trade continuing.\nDon't confuse the market taking a breather with the end of the trade.","news_type":1},"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166232328,"gmtCreate":1624010782264,"gmtModify":1703826486842,"author":{"id":"3582358356914075","authorId":"3582358356914075","name":"hongweiiewgn","avatar":"https://static.tigerbbs.com/2f1848f0d6e2963f698914aeff51448e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582358356914075","authorIdStr":"3582358356914075"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/166232328","repostId":"2144742013","repostType":4,"repost":{"id":"2144742013","pubTimestamp":1624008600,"share":"https://ttm.financial/m/news/2144742013?lang=&edition=fundamental","pubTime":"2021-06-18 17:30","market":"us","language":"en","title":"Is Tattooed Chef the Next Beyond Meat? 3 Points to Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2144742013","media":"Motley Fool","summary":"The company is generating growth, but its bottom line is cause for some concern.","content":"<p>Having gone public via a SPAC (special purpose acquisition company) merger at the start of the current SPAC craze back in mid-2020, <b>Tattooed Chef</b> (NASDAQ:TTCF) says in its own investor materials that it's looking to be a disruptive upstart in the fast-growing plant-based foods sector. After a pair of recent acquisitions and a toothsome first-quarter earnings report, investors rewarded the company with a 20% share price increase in May.</p>\n<p>An investor conference began on June 16, allowing investors to get a better look at the company's recent background and get clues as to where it might be going. Here are three points you may want to consider while deciding if Tattooed Chef is the next <b>Beyond Meat</b> (NASDAQ:BYND) or if its weaknesses will limit its growth.</p>\n<h2>1. Tattooed Chef's operations are thriving</h2>\n<p>Despite the company having a traditional advertising budget of zero, Tattooed Chef's sales are booming, with overall revenue jumping 59% year over year from $33.2 million in Q1 2020 to $52.7 million in Q1 2021. An even more favorable sign for customer loyalty and brand recognition was the 105% year-over-year surge in products specifically branded with the Tattooed Chef name (the company also produces store-brand food products for various retailers). The company is projecting between $235 million and $242 million in total revenue for 2021 and a minimum of $300 million in the coming year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9b21e26263590dd121318b21e10d79a\" tg-width=\"700\" tg-height=\"464\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<p>The plant-based food maker is also achieving notable growth in the extent of its distribution network. According to company data, the number of stores carrying its products soared 41% between Dec. 31, 2020, and March 31, 2021, rising from 4,300 to 6,065. Points of distribution jumped to 31,000 from 23,000, an increase of nearly 35%.</p>\n<p>During the Q1 earnings conference call, CEO Salvatore Galletti said that by Q2's end on June 30, \"We expect to be an additional 1,162 stores with 8,000 new points of distribution, including a number of larger grocery chains.\" He added, \"We are confident we can achieve our 2021 objective of 10,000 stores and 65,000 points of distribution for Tattooed Chef by year end.\"</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> early May acquisitions by Tattooed Chef, costing the company a total of $35 million, could be a catalyst for stronger growth and expanded production, too. Tattooed snapped up Karsten Tortilla Factory and New Mexico Food Distributors. According to Galletti, it \"will be immediately addressing the $1 billion Frozen Mexican Food category once the transactions close,\" and will use the new acquisitions as a stepping stone into the $20 billion market for \"Hispanic/Southwest\" food.</p>\n<p>With Abasto reporting around two-thirds of Americans (233 million) using at least some Mexican foods or recipes according to Statista research, and growth in this type of dining expected to continue, Tattooed Chef's move helps it establish a new position in a strong market sector. The purchase also adds 118,000 square feet of production facilities to its total, helping prevent a processing bottleneck during this period of rapid sales growth. Galletti remarks the two acquisitions are projected to \"contribute up to $200 million annually in revenue in the next two to three years and create significant value.\"</p>\n<p>The company is also expanding from a focus on frozen and refrigerated foods to shelf-stable foods (which it refers to with the buzzword phrase \"ambient foods\" in company literature). With sales of major shelf-stable food categories such as vegetables and soups having grown anywhere from 28% to 31.3% in 2020 according to market research firm IRI, this could be another potential sales driver.</p>\n<h2>2. It's not all sunshine for the company</h2>\n<p>Despite its skyrocketing sales and its relative freedom from the expense of a significant advertising budget, Tattooed Chef still registered a net loss in Q1 2021. The company's bottom line has worsened year over year: It produced positive $5.9 million net income in Q1 2020 versus a $7.9 million net loss in the same period this year. It has seen a rise in operating expenses, including a few million directed towards marketing and several million directed towards stock compensation.</p>\n<p>While Tattooed Chef makes plant-based cauliflower burgers, it simply doesn't have the serious research and development (R&amp;D) muscle of Beyond Meat or privately held Impossible Foods to produce meat substitutes at the same level. While Beyond and Impossible maintain laboratories and fund teams of scientists to develop plant protein faux meat closely mimicking the flavor, texture, cooking characteristics, nutrition, and even bleeding of actual meat and are working on similarly advanced plant-based milk and eggs, Tattooed Chef's cauliflower burgers are just spiced and breaded cauliflower patties, a far more casual approach.</p>\n<p>Given that Beyond and Impossible owe their success to the accurate simulation of meat in a plant-based format, Tattooed Chef seems unlikely to tap strongly into that growth market. Its acai bowls, smoothie bowls, and other products, while proving salable, don't have the cutting-edge sales leverage of the advanced faux meats offered by its competitors and might be readily substituted with other companies' frozen meal bowls. Tattooed Chef, at this point, appears to lack the powerful, clear-cut product differentiation at the heart of the success of manufacturers like Beyond Meat.</p>\n<h2>3. The high short interest in Tattooed Chef is a wild card</h2>\n<p>One factor with potentially unpredictable consequences for Tattooed Chef is high short interest, standing at slightly over 36% at the start of June. Under ordinary market conditions, this would be a negative, indicating a large cohort of short-sellers have done their due diligence and found the company's fundamentals to be significantly lacking. A few years ago, this beefy short interest would have been a definitive warning sign about the company's future.</p>\n<p>In today's stock market climate, however, the high short interest could potentially attract the attention of large numbers of retail investors, such as those from the millions-strong r/WallStreetBets Reddit community. Noted for their tremendous short squeeze on the stock of video game seller <b>GameStop</b> and a growing handful of other \"meme stocks,\" these Redditors and other small investors remain on the lookout for heavily shorted stocks to buy in quantity.</p>\n<p>While Tattooed Chef seems to have drawn relatively little notice from these investors up until now, the quest for the next short squeeze takedown could eventually see the company become a meme stock, too. In this case, an attempted squeeze by WallStreetBets readers could pump immense streams of cash into Tattooed Chef, giving the company ample liquidity to aggressively pursue expansion, boost production capacity, and increase the range of product development.</p>\n<h2>Should you add a taste of Tattooed Chef to your portfolio?</h2>\n<p>While Tattooed Chef isn't making the groundbreaking plant-based meat or dairy products of Beyond Meat or Impossible Foods, it appears to have some real potential to become a profitable midsize vegetarian and vegan meal company. Its troubled bottom line and high short interest point to some risk, though, as noted, the latter could become an asset if the company becomes a meme stock and draws a major short squeeze cash inflow from Reddit retail investors at some point.</p>\n<p>Even without such a windfall, however, Tattooed Chef's entry into the Mexican-style food market, along with its rapid development of distribution channels, look like bullish indicators. While the company's future is uncertain and carries some risk, Fools investing in food stocks&nbsp;may want to consider adding at least a few of the company's shares to their holdings.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tattooed Chef the Next Beyond Meat? 3 Points to Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tattooed Chef the Next Beyond Meat? 3 Points to Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/17/tattooed-chef-next-beyond-meat-points-consider/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Having gone public via a SPAC (special purpose acquisition company) merger at the start of the current SPAC craze back in mid-2020, Tattooed Chef (NASDAQ:TTCF) says in its own investor materials that ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/17/tattooed-chef-next-beyond-meat-points-consider/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","PCOM":"Points International"},"source_url":"https://www.fool.com/investing/2021/06/17/tattooed-chef-next-beyond-meat-points-consider/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144742013","content_text":"Having gone public via a SPAC (special purpose acquisition company) merger at the start of the current SPAC craze back in mid-2020, Tattooed Chef (NASDAQ:TTCF) says in its own investor materials that it's looking to be a disruptive upstart in the fast-growing plant-based foods sector. After a pair of recent acquisitions and a toothsome first-quarter earnings report, investors rewarded the company with a 20% share price increase in May.\nAn investor conference began on June 16, allowing investors to get a better look at the company's recent background and get clues as to where it might be going. Here are three points you may want to consider while deciding if Tattooed Chef is the next Beyond Meat (NASDAQ:BYND) or if its weaknesses will limit its growth.\n1. Tattooed Chef's operations are thriving\nDespite the company having a traditional advertising budget of zero, Tattooed Chef's sales are booming, with overall revenue jumping 59% year over year from $33.2 million in Q1 2020 to $52.7 million in Q1 2021. An even more favorable sign for customer loyalty and brand recognition was the 105% year-over-year surge in products specifically branded with the Tattooed Chef name (the company also produces store-brand food products for various retailers). The company is projecting between $235 million and $242 million in total revenue for 2021 and a minimum of $300 million in the coming year.\nImage source: Getty Images.\nThe plant-based food maker is also achieving notable growth in the extent of its distribution network. According to company data, the number of stores carrying its products soared 41% between Dec. 31, 2020, and March 31, 2021, rising from 4,300 to 6,065. Points of distribution jumped to 31,000 from 23,000, an increase of nearly 35%.\nDuring the Q1 earnings conference call, CEO Salvatore Galletti said that by Q2's end on June 30, \"We expect to be an additional 1,162 stores with 8,000 new points of distribution, including a number of larger grocery chains.\" He added, \"We are confident we can achieve our 2021 objective of 10,000 stores and 65,000 points of distribution for Tattooed Chef by year end.\"\nTwo early May acquisitions by Tattooed Chef, costing the company a total of $35 million, could be a catalyst for stronger growth and expanded production, too. Tattooed snapped up Karsten Tortilla Factory and New Mexico Food Distributors. According to Galletti, it \"will be immediately addressing the $1 billion Frozen Mexican Food category once the transactions close,\" and will use the new acquisitions as a stepping stone into the $20 billion market for \"Hispanic/Southwest\" food.\nWith Abasto reporting around two-thirds of Americans (233 million) using at least some Mexican foods or recipes according to Statista research, and growth in this type of dining expected to continue, Tattooed Chef's move helps it establish a new position in a strong market sector. The purchase also adds 118,000 square feet of production facilities to its total, helping prevent a processing bottleneck during this period of rapid sales growth. Galletti remarks the two acquisitions are projected to \"contribute up to $200 million annually in revenue in the next two to three years and create significant value.\"\nThe company is also expanding from a focus on frozen and refrigerated foods to shelf-stable foods (which it refers to with the buzzword phrase \"ambient foods\" in company literature). With sales of major shelf-stable food categories such as vegetables and soups having grown anywhere from 28% to 31.3% in 2020 according to market research firm IRI, this could be another potential sales driver.\n2. It's not all sunshine for the company\nDespite its skyrocketing sales and its relative freedom from the expense of a significant advertising budget, Tattooed Chef still registered a net loss in Q1 2021. The company's bottom line has worsened year over year: It produced positive $5.9 million net income in Q1 2020 versus a $7.9 million net loss in the same period this year. It has seen a rise in operating expenses, including a few million directed towards marketing and several million directed towards stock compensation.\nWhile Tattooed Chef makes plant-based cauliflower burgers, it simply doesn't have the serious research and development (R&D) muscle of Beyond Meat or privately held Impossible Foods to produce meat substitutes at the same level. While Beyond and Impossible maintain laboratories and fund teams of scientists to develop plant protein faux meat closely mimicking the flavor, texture, cooking characteristics, nutrition, and even bleeding of actual meat and are working on similarly advanced plant-based milk and eggs, Tattooed Chef's cauliflower burgers are just spiced and breaded cauliflower patties, a far more casual approach.\nGiven that Beyond and Impossible owe their success to the accurate simulation of meat in a plant-based format, Tattooed Chef seems unlikely to tap strongly into that growth market. Its acai bowls, smoothie bowls, and other products, while proving salable, don't have the cutting-edge sales leverage of the advanced faux meats offered by its competitors and might be readily substituted with other companies' frozen meal bowls. Tattooed Chef, at this point, appears to lack the powerful, clear-cut product differentiation at the heart of the success of manufacturers like Beyond Meat.\n3. The high short interest in Tattooed Chef is a wild card\nOne factor with potentially unpredictable consequences for Tattooed Chef is high short interest, standing at slightly over 36% at the start of June. Under ordinary market conditions, this would be a negative, indicating a large cohort of short-sellers have done their due diligence and found the company's fundamentals to be significantly lacking. A few years ago, this beefy short interest would have been a definitive warning sign about the company's future.\nIn today's stock market climate, however, the high short interest could potentially attract the attention of large numbers of retail investors, such as those from the millions-strong r/WallStreetBets Reddit community. Noted for their tremendous short squeeze on the stock of video game seller GameStop and a growing handful of other \"meme stocks,\" these Redditors and other small investors remain on the lookout for heavily shorted stocks to buy in quantity.\nWhile Tattooed Chef seems to have drawn relatively little notice from these investors up until now, the quest for the next short squeeze takedown could eventually see the company become a meme stock, too. In this case, an attempted squeeze by WallStreetBets readers could pump immense streams of cash into Tattooed Chef, giving the company ample liquidity to aggressively pursue expansion, boost production capacity, and increase the range of product development.\nShould you add a taste of Tattooed Chef to your portfolio?\nWhile Tattooed Chef isn't making the groundbreaking plant-based meat or dairy products of Beyond Meat or Impossible Foods, it appears to have some real potential to become a profitable midsize vegetarian and vegan meal company. Its troubled bottom line and high short interest point to some risk, though, as noted, the latter could become an asset if the company becomes a meme stock and draws a major short squeeze cash inflow from Reddit retail investors at some point.\nEven without such a windfall, however, Tattooed Chef's entry into the Mexican-style food market, along with its rapid development of distribution channels, look like bullish indicators. While the company's future is uncertain and carries some risk, Fools investing in food stocks may want to consider adding at least a few of the company's shares to their holdings.","news_type":1},"isVote":1,"tweetType":1,"viewCount":597,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166236555,"gmtCreate":1624010750877,"gmtModify":1703826486034,"author":{"id":"3582358356914075","authorId":"3582358356914075","name":"hongweiiewgn","avatar":"https://static.tigerbbs.com/2f1848f0d6e2963f698914aeff51448e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582358356914075","authorIdStr":"3582358356914075"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166236555","repostId":"1166489816","repostType":4,"repost":{"id":"1166489816","pubTimestamp":1624009298,"share":"https://ttm.financial/m/news/1166489816?lang=&edition=fundamental","pubTime":"2021-06-18 17:41","market":"us","language":"en","title":"Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1166489816","media":"seekingalpha","summary":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine ","content":"<ul>\n <li>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase&nbsp;2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.</li>\n <li>The trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.</li>\n <li>Secondary endpoints include ORR in the single agent arms, duration of response, and safety.</li>\n <li>The first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.</li>\n <li>This Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.</li>\n <li>The Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).</li>\n <li>The BNT111-01 trial is being conducted in collaboration with Regeneron.</li>\n <li>BioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1166489816","content_text":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.\nThe trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.\nSecondary endpoints include ORR in the single agent arms, duration of response, and safety.\nThe first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.\nThis Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.\nThe Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).\nThe BNT111-01 trial is being conducted in collaboration with Regeneron.\nBioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant","news_type":1},"isVote":1,"tweetType":1,"viewCount":553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":153237905,"gmtCreate":1625026644707,"gmtModify":1703850446664,"author":{"id":"3582358356914075","authorId":"3582358356914075","name":"hongweiiewgn","avatar":"https://static.tigerbbs.com/2f1848f0d6e2963f698914aeff51448e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582358356914075","authorIdStr":"3582358356914075"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/153237905","repostId":"2147585034","repostType":4,"repost":{"id":"2147585034","pubTimestamp":1625024760,"share":"https://ttm.financial/m/news/2147585034?lang=&edition=fundamental","pubTime":"2021-06-30 11:46","market":"us","language":"en","title":"This Hot Reddit Stock Just Gave Investors an Ominous Warning","url":"https://stock-news.laohu8.com/highlight/detail?id=2147585034","media":"Motley Fool","summary":"It's a warning that investors should take seriously.","content":"<p>This year was shaping up to be a miserable <a href=\"https://laohu8.com/S/AONE\">one</a> for&nbsp;<b>Clover Health</b> (NASDAQ:CLOV). Note the use of the past tense in that statement, though. Thanks in large part to Reddit users piling on, Clover's shares have soared in recent weeks.</p>\n<p>Don't think that the waters are safe to jump aboard the bandwagon for Clover Health yet, however.&nbsp;Here's why this hot Reddit stock just gave investors an ominous warning.</p>\n<h2>Brutal honesty</h2>\n<p>All publicly traded companies want investors to buy their shares. Buying tends to beget more buying, which pushes the stock price up. It's rare that any company warns investors not to buy its stock. But that's exactly what Clover Health did recently.</p>\n<p>Companies that plan to issue additional shares file a prospectus with the U.S. Securities and Exchange Commission (SEC). This prospectus gives potential investors a lot of information about the business and lays out the key reasons why they might want to buy the new shares.</p>\n<p>Clover Health filed such a prospectus earlier this year, outlining its intent to issue additional Class B shares. These shares don't have the same level of voting rights as its Class A shares. Last week, the company submitted an amendment to the SEC for this prospectus. And that amendment contained a brutally honest message for potential investors.</p>\n<p>The company acknowledged that its recent gains could be due to a short squeeze. Because of the potential for an additional short squeeze and its aftermath, Clover Health gave an unusually stark warning to investors: \"Under the circumstances, we caution you against investing in our Class B common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.\" It also noted, \"Investors that purchase shares of our Class A common stock during a short squeeze may lose a significant portion of their investment.\"</p>\n<h2>No fear?</h2>\n<p>Clover Health explained clearly what could happen with both its Class A and Class B shares. The company stated that if another short squeeze happens, once short-sellers cover their positions or if investors otherwise think the short squeeze has run its course, its stock price could fall quickly.</p>\n<p>You might think that such an ominous warning would scare off many investors. Nope. Instead, it produced an opposite effect. Last week, shares of Clover Health soared by a double-digit percentage immediately after the company's amended prospectus with the serious warning was submitted to the SEC.</p>\n<p>This reaction might seem counterintuitive. After all, Clover Health informed investors in no uncertain terms about the risks they face with buying the stock. So why did the shares of the company surge instead of sink? I think there are different reasons for different investors.</p>\n<p>Some truly believe in Clover Health and are willing to hold onto the stock regardless of what happens over the short term. Others are fully aware that the gains generated by a short squeeze could evaporate quickly but think they'll be able to sell in time to still make a big profit. Unfortunately, there could also be some who are new to investing and didn't pay attention to or didn't understand Clover Health's cautionary message.</p>\n<h2>Business vs. stock</h2>\n<p>It's always wise to think of buying a stock as buying a part of a business. That's exactly what you're doing when you buy shares of Clover Health or any other company. When the underlying business is strong and has great prospects, you don't have to be concerned about short-term volatility with the share price.</p>\n<p>However, there are times when share prices get way out of alignment with the prospects of the underlying business. Short squeezes can often make this happen. In these cases, it's especially important to be careful in buying a stock. Sure, you're still buying a part of a business -- but you can pay a lot more than the business is actually worth.</p>\n<p>In my view, there are several reasons to like Clover Health's underlying business. The company has an intriguing technology that physicians use. It's expanding into the original Medicare market, a move that could boost sales tremendously. Clover Health has a visionary management team.</p>\n<p>But buying a stock that's a short squeeze candidate is risky if you aren't ready, willing, and able to sell shares immediately once the short squeeze ends. When a company issues a warning like Clover Health just did, the smart thing to do is to listen and take that warning seriously.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Hot Reddit Stock Just Gave Investors an Ominous Warning</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Hot Reddit Stock Just Gave Investors an Ominous Warning\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 11:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/29/this-hot-reddit-stock-just-gave-investors-an-omino/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This year was shaping up to be a miserable one for Clover Health (NASDAQ:CLOV). Note the use of the past tense in that statement, though. Thanks in large part to Reddit users piling on, Clover's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/29/this-hot-reddit-stock-just-gave-investors-an-omino/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://www.fool.com/investing/2021/06/29/this-hot-reddit-stock-just-gave-investors-an-omino/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147585034","content_text":"This year was shaping up to be a miserable one for Clover Health (NASDAQ:CLOV). Note the use of the past tense in that statement, though. Thanks in large part to Reddit users piling on, Clover's shares have soared in recent weeks.\nDon't think that the waters are safe to jump aboard the bandwagon for Clover Health yet, however. Here's why this hot Reddit stock just gave investors an ominous warning.\nBrutal honesty\nAll publicly traded companies want investors to buy their shares. Buying tends to beget more buying, which pushes the stock price up. It's rare that any company warns investors not to buy its stock. But that's exactly what Clover Health did recently.\nCompanies that plan to issue additional shares file a prospectus with the U.S. Securities and Exchange Commission (SEC). This prospectus gives potential investors a lot of information about the business and lays out the key reasons why they might want to buy the new shares.\nClover Health filed such a prospectus earlier this year, outlining its intent to issue additional Class B shares. These shares don't have the same level of voting rights as its Class A shares. Last week, the company submitted an amendment to the SEC for this prospectus. And that amendment contained a brutally honest message for potential investors.\nThe company acknowledged that its recent gains could be due to a short squeeze. Because of the potential for an additional short squeeze and its aftermath, Clover Health gave an unusually stark warning to investors: \"Under the circumstances, we caution you against investing in our Class B common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment.\" It also noted, \"Investors that purchase shares of our Class A common stock during a short squeeze may lose a significant portion of their investment.\"\nNo fear?\nClover Health explained clearly what could happen with both its Class A and Class B shares. The company stated that if another short squeeze happens, once short-sellers cover their positions or if investors otherwise think the short squeeze has run its course, its stock price could fall quickly.\nYou might think that such an ominous warning would scare off many investors. Nope. Instead, it produced an opposite effect. Last week, shares of Clover Health soared by a double-digit percentage immediately after the company's amended prospectus with the serious warning was submitted to the SEC.\nThis reaction might seem counterintuitive. After all, Clover Health informed investors in no uncertain terms about the risks they face with buying the stock. So why did the shares of the company surge instead of sink? I think there are different reasons for different investors.\nSome truly believe in Clover Health and are willing to hold onto the stock regardless of what happens over the short term. Others are fully aware that the gains generated by a short squeeze could evaporate quickly but think they'll be able to sell in time to still make a big profit. Unfortunately, there could also be some who are new to investing and didn't pay attention to or didn't understand Clover Health's cautionary message.\nBusiness vs. stock\nIt's always wise to think of buying a stock as buying a part of a business. That's exactly what you're doing when you buy shares of Clover Health or any other company. When the underlying business is strong and has great prospects, you don't have to be concerned about short-term volatility with the share price.\nHowever, there are times when share prices get way out of alignment with the prospects of the underlying business. Short squeezes can often make this happen. In these cases, it's especially important to be careful in buying a stock. Sure, you're still buying a part of a business -- but you can pay a lot more than the business is actually worth.\nIn my view, there are several reasons to like Clover Health's underlying business. The company has an intriguing technology that physicians use. It's expanding into the original Medicare market, a move that could boost sales tremendously. Clover Health has a visionary management team.\nBut buying a stock that's a short squeeze candidate is risky if you aren't ready, willing, and able to sell shares immediately once the short squeeze ends. When a company issues a warning like Clover Health just did, the smart thing to do is to listen and take that warning seriously.","news_type":1},"isVote":1,"tweetType":1,"viewCount":951,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122594155,"gmtCreate":1624627000477,"gmtModify":1703842055198,"author":{"id":"3582358356914075","authorId":"3582358356914075","name":"hongweiiewgn","avatar":"https://static.tigerbbs.com/2f1848f0d6e2963f698914aeff51448e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582358356914075","authorIdStr":"3582358356914075"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/122594155","repostId":"1101793896","repostType":2,"repost":{"id":"1101793896","pubTimestamp":1624624097,"share":"https://ttm.financial/m/news/1101793896?lang=&edition=fundamental","pubTime":"2021-06-25 20:28","market":"us","language":"en","title":"AMC stock set to snap 4-week win streak","url":"https://stock-news.laohu8.com/highlight/detail?id=1101793896","media":"MarketWatch","summary":"Shares of AMC Entertainment Holdings Inc.AMC,-2.74%fell 2.5% in premarket trading Friday, which puts","content":"<p>Shares of AMC Entertainment Holdings Inc.AMC,-2.74%fell 2.5% in premarket trading Friday, which putsthe meme stockon track to snap a four-week win streak in which it rocketed nearly fivefold. </p>\n<p>The movie theater chain's stock has lost 4.3% so far this week, after soaring 390.6% over the previous four weeks. During the weekly win streak, the stock had closed at a record $62.55 on June 2. </p>\n<p>Among&nbsp;other meme stocks, GameStop Corp.GME,-3.21%rose 1.1% in premarket trading Friday, which would put it on track to snap a two-week losing streak in which it shed 13.9%. GameStop shares have slipped 0.7% week-to-date through Thursday. </p>\n<p>Separately, the S&amp;P 500SPX,+0.58%has fallen 0.7% week to date, putting it on track for a third-straight weekly decline.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC stock set to snap 4-week win streak</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC stock set to snap 4-week win streak\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 20:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/amc-stock-set-to-snap-4-week-win-streak-2021-06-25?siteid=rss&utm_campaign=Feed%3A+marketwatch%2Fmarketpulse+%28MarketWatch.com+-+MarketPulse%29&utm_medium=feed&utm_source=feedburner><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of AMC Entertainment Holdings Inc.AMC,-2.74%fell 2.5% in premarket trading Friday, which putsthe meme stockon track to snap a four-week win streak in which it rocketed nearly fivefold. \nThe ...</p>\n\n<a href=\"https://www.marketwatch.com/story/amc-stock-set-to-snap-4-week-win-streak-2021-06-25?siteid=rss&utm_campaign=Feed%3A+marketwatch%2Fmarketpulse+%28MarketWatch.com+-+MarketPulse%29&utm_medium=feed&utm_source=feedburner\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.marketwatch.com/story/amc-stock-set-to-snap-4-week-win-streak-2021-06-25?siteid=rss&utm_campaign=Feed%3A+marketwatch%2Fmarketpulse+%28MarketWatch.com+-+MarketPulse%29&utm_medium=feed&utm_source=feedburner","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101793896","content_text":"Shares of AMC Entertainment Holdings Inc.AMC,-2.74%fell 2.5% in premarket trading Friday, which putsthe meme stockon track to snap a four-week win streak in which it rocketed nearly fivefold. \nThe movie theater chain's stock has lost 4.3% so far this week, after soaring 390.6% over the previous four weeks. During the weekly win streak, the stock had closed at a record $62.55 on June 2. \nAmong other meme stocks, GameStop Corp.GME,-3.21%rose 1.1% in premarket trading Friday, which would put it on track to snap a two-week losing streak in which it shed 13.9%. GameStop shares have slipped 0.7% week-to-date through Thursday. \nSeparately, the S&P 500SPX,+0.58%has fallen 0.7% week to date, putting it on track for a third-straight weekly decline.","news_type":1},"isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166236555,"gmtCreate":1624010750877,"gmtModify":1703826486034,"author":{"id":"3582358356914075","authorId":"3582358356914075","name":"hongweiiewgn","avatar":"https://static.tigerbbs.com/2f1848f0d6e2963f698914aeff51448e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582358356914075","authorIdStr":"3582358356914075"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/166236555","repostId":"1166489816","repostType":4,"repost":{"id":"1166489816","pubTimestamp":1624009298,"share":"https://ttm.financial/m/news/1166489816?lang=&edition=fundamental","pubTime":"2021-06-18 17:41","market":"us","language":"en","title":"Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1166489816","media":"seekingalpha","summary":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine ","content":"<ul>\n <li>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase&nbsp;2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.</li>\n <li>The trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.</li>\n <li>Secondary endpoints include ORR in the single agent arms, duration of response, and safety.</li>\n <li>The first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.</li>\n <li>This Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.</li>\n <li>The Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).</li>\n <li>The BNT111-01 trial is being conducted in collaboration with Regeneron.</li>\n <li>BioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1166489816","content_text":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.\nThe trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.\nSecondary endpoints include ORR in the single agent arms, duration of response, and safety.\nThe first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.\nThis Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.\nThe Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).\nThe BNT111-01 trial is being conducted in collaboration with Regeneron.\nBioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant","news_type":1},"isVote":1,"tweetType":1,"viewCount":553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166232328,"gmtCreate":1624010782264,"gmtModify":1703826486842,"author":{"id":"3582358356914075","authorId":"3582358356914075","name":"hongweiiewgn","avatar":"https://static.tigerbbs.com/2f1848f0d6e2963f698914aeff51448e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582358356914075","authorIdStr":"3582358356914075"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/166232328","repostId":"2144742013","repostType":4,"repost":{"id":"2144742013","pubTimestamp":1624008600,"share":"https://ttm.financial/m/news/2144742013?lang=&edition=fundamental","pubTime":"2021-06-18 17:30","market":"us","language":"en","title":"Is Tattooed Chef the Next Beyond Meat? 3 Points to Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2144742013","media":"Motley Fool","summary":"The company is generating growth, but its bottom line is cause for some concern.","content":"<p>Having gone public via a SPAC (special purpose acquisition company) merger at the start of the current SPAC craze back in mid-2020, <b>Tattooed Chef</b> (NASDAQ:TTCF) says in its own investor materials that it's looking to be a disruptive upstart in the fast-growing plant-based foods sector. After a pair of recent acquisitions and a toothsome first-quarter earnings report, investors rewarded the company with a 20% share price increase in May.</p>\n<p>An investor conference began on June 16, allowing investors to get a better look at the company's recent background and get clues as to where it might be going. Here are three points you may want to consider while deciding if Tattooed Chef is the next <b>Beyond Meat</b> (NASDAQ:BYND) or if its weaknesses will limit its growth.</p>\n<h2>1. Tattooed Chef's operations are thriving</h2>\n<p>Despite the company having a traditional advertising budget of zero, Tattooed Chef's sales are booming, with overall revenue jumping 59% year over year from $33.2 million in Q1 2020 to $52.7 million in Q1 2021. An even more favorable sign for customer loyalty and brand recognition was the 105% year-over-year surge in products specifically branded with the Tattooed Chef name (the company also produces store-brand food products for various retailers). The company is projecting between $235 million and $242 million in total revenue for 2021 and a minimum of $300 million in the coming year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d9b21e26263590dd121318b21e10d79a\" tg-width=\"700\" tg-height=\"464\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<p>The plant-based food maker is also achieving notable growth in the extent of its distribution network. According to company data, the number of stores carrying its products soared 41% between Dec. 31, 2020, and March 31, 2021, rising from 4,300 to 6,065. Points of distribution jumped to 31,000 from 23,000, an increase of nearly 35%.</p>\n<p>During the Q1 earnings conference call, CEO Salvatore Galletti said that by Q2's end on June 30, \"We expect to be an additional 1,162 stores with 8,000 new points of distribution, including a number of larger grocery chains.\" He added, \"We are confident we can achieve our 2021 objective of 10,000 stores and 65,000 points of distribution for Tattooed Chef by year end.\"</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> early May acquisitions by Tattooed Chef, costing the company a total of $35 million, could be a catalyst for stronger growth and expanded production, too. Tattooed snapped up Karsten Tortilla Factory and New Mexico Food Distributors. According to Galletti, it \"will be immediately addressing the $1 billion Frozen Mexican Food category once the transactions close,\" and will use the new acquisitions as a stepping stone into the $20 billion market for \"Hispanic/Southwest\" food.</p>\n<p>With Abasto reporting around two-thirds of Americans (233 million) using at least some Mexican foods or recipes according to Statista research, and growth in this type of dining expected to continue, Tattooed Chef's move helps it establish a new position in a strong market sector. The purchase also adds 118,000 square feet of production facilities to its total, helping prevent a processing bottleneck during this period of rapid sales growth. Galletti remarks the two acquisitions are projected to \"contribute up to $200 million annually in revenue in the next two to three years and create significant value.\"</p>\n<p>The company is also expanding from a focus on frozen and refrigerated foods to shelf-stable foods (which it refers to with the buzzword phrase \"ambient foods\" in company literature). With sales of major shelf-stable food categories such as vegetables and soups having grown anywhere from 28% to 31.3% in 2020 according to market research firm IRI, this could be another potential sales driver.</p>\n<h2>2. It's not all sunshine for the company</h2>\n<p>Despite its skyrocketing sales and its relative freedom from the expense of a significant advertising budget, Tattooed Chef still registered a net loss in Q1 2021. The company's bottom line has worsened year over year: It produced positive $5.9 million net income in Q1 2020 versus a $7.9 million net loss in the same period this year. It has seen a rise in operating expenses, including a few million directed towards marketing and several million directed towards stock compensation.</p>\n<p>While Tattooed Chef makes plant-based cauliflower burgers, it simply doesn't have the serious research and development (R&amp;D) muscle of Beyond Meat or privately held Impossible Foods to produce meat substitutes at the same level. While Beyond and Impossible maintain laboratories and fund teams of scientists to develop plant protein faux meat closely mimicking the flavor, texture, cooking characteristics, nutrition, and even bleeding of actual meat and are working on similarly advanced plant-based milk and eggs, Tattooed Chef's cauliflower burgers are just spiced and breaded cauliflower patties, a far more casual approach.</p>\n<p>Given that Beyond and Impossible owe their success to the accurate simulation of meat in a plant-based format, Tattooed Chef seems unlikely to tap strongly into that growth market. Its acai bowls, smoothie bowls, and other products, while proving salable, don't have the cutting-edge sales leverage of the advanced faux meats offered by its competitors and might be readily substituted with other companies' frozen meal bowls. Tattooed Chef, at this point, appears to lack the powerful, clear-cut product differentiation at the heart of the success of manufacturers like Beyond Meat.</p>\n<h2>3. The high short interest in Tattooed Chef is a wild card</h2>\n<p>One factor with potentially unpredictable consequences for Tattooed Chef is high short interest, standing at slightly over 36% at the start of June. Under ordinary market conditions, this would be a negative, indicating a large cohort of short-sellers have done their due diligence and found the company's fundamentals to be significantly lacking. A few years ago, this beefy short interest would have been a definitive warning sign about the company's future.</p>\n<p>In today's stock market climate, however, the high short interest could potentially attract the attention of large numbers of retail investors, such as those from the millions-strong r/WallStreetBets Reddit community. Noted for their tremendous short squeeze on the stock of video game seller <b>GameStop</b> and a growing handful of other \"meme stocks,\" these Redditors and other small investors remain on the lookout for heavily shorted stocks to buy in quantity.</p>\n<p>While Tattooed Chef seems to have drawn relatively little notice from these investors up until now, the quest for the next short squeeze takedown could eventually see the company become a meme stock, too. In this case, an attempted squeeze by WallStreetBets readers could pump immense streams of cash into Tattooed Chef, giving the company ample liquidity to aggressively pursue expansion, boost production capacity, and increase the range of product development.</p>\n<h2>Should you add a taste of Tattooed Chef to your portfolio?</h2>\n<p>While Tattooed Chef isn't making the groundbreaking plant-based meat or dairy products of Beyond Meat or Impossible Foods, it appears to have some real potential to become a profitable midsize vegetarian and vegan meal company. Its troubled bottom line and high short interest point to some risk, though, as noted, the latter could become an asset if the company becomes a meme stock and draws a major short squeeze cash inflow from Reddit retail investors at some point.</p>\n<p>Even without such a windfall, however, Tattooed Chef's entry into the Mexican-style food market, along with its rapid development of distribution channels, look like bullish indicators. While the company's future is uncertain and carries some risk, Fools investing in food stocks&nbsp;may want to consider adding at least a few of the company's shares to their holdings.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Tattooed Chef the Next Beyond Meat? 3 Points to Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Tattooed Chef the Next Beyond Meat? 3 Points to Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/17/tattooed-chef-next-beyond-meat-points-consider/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Having gone public via a SPAC (special purpose acquisition company) merger at the start of the current SPAC craze back in mid-2020, Tattooed Chef (NASDAQ:TTCF) says in its own investor materials that ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/17/tattooed-chef-next-beyond-meat-points-consider/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc.","PCOM":"Points International"},"source_url":"https://www.fool.com/investing/2021/06/17/tattooed-chef-next-beyond-meat-points-consider/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144742013","content_text":"Having gone public via a SPAC (special purpose acquisition company) merger at the start of the current SPAC craze back in mid-2020, Tattooed Chef (NASDAQ:TTCF) says in its own investor materials that it's looking to be a disruptive upstart in the fast-growing plant-based foods sector. After a pair of recent acquisitions and a toothsome first-quarter earnings report, investors rewarded the company with a 20% share price increase in May.\nAn investor conference began on June 16, allowing investors to get a better look at the company's recent background and get clues as to where it might be going. Here are three points you may want to consider while deciding if Tattooed Chef is the next Beyond Meat (NASDAQ:BYND) or if its weaknesses will limit its growth.\n1. Tattooed Chef's operations are thriving\nDespite the company having a traditional advertising budget of zero, Tattooed Chef's sales are booming, with overall revenue jumping 59% year over year from $33.2 million in Q1 2020 to $52.7 million in Q1 2021. An even more favorable sign for customer loyalty and brand recognition was the 105% year-over-year surge in products specifically branded with the Tattooed Chef name (the company also produces store-brand food products for various retailers). The company is projecting between $235 million and $242 million in total revenue for 2021 and a minimum of $300 million in the coming year.\nImage source: Getty Images.\nThe plant-based food maker is also achieving notable growth in the extent of its distribution network. According to company data, the number of stores carrying its products soared 41% between Dec. 31, 2020, and March 31, 2021, rising from 4,300 to 6,065. Points of distribution jumped to 31,000 from 23,000, an increase of nearly 35%.\nDuring the Q1 earnings conference call, CEO Salvatore Galletti said that by Q2's end on June 30, \"We expect to be an additional 1,162 stores with 8,000 new points of distribution, including a number of larger grocery chains.\" He added, \"We are confident we can achieve our 2021 objective of 10,000 stores and 65,000 points of distribution for Tattooed Chef by year end.\"\nTwo early May acquisitions by Tattooed Chef, costing the company a total of $35 million, could be a catalyst for stronger growth and expanded production, too. Tattooed snapped up Karsten Tortilla Factory and New Mexico Food Distributors. According to Galletti, it \"will be immediately addressing the $1 billion Frozen Mexican Food category once the transactions close,\" and will use the new acquisitions as a stepping stone into the $20 billion market for \"Hispanic/Southwest\" food.\nWith Abasto reporting around two-thirds of Americans (233 million) using at least some Mexican foods or recipes according to Statista research, and growth in this type of dining expected to continue, Tattooed Chef's move helps it establish a new position in a strong market sector. The purchase also adds 118,000 square feet of production facilities to its total, helping prevent a processing bottleneck during this period of rapid sales growth. Galletti remarks the two acquisitions are projected to \"contribute up to $200 million annually in revenue in the next two to three years and create significant value.\"\nThe company is also expanding from a focus on frozen and refrigerated foods to shelf-stable foods (which it refers to with the buzzword phrase \"ambient foods\" in company literature). With sales of major shelf-stable food categories such as vegetables and soups having grown anywhere from 28% to 31.3% in 2020 according to market research firm IRI, this could be another potential sales driver.\n2. It's not all sunshine for the company\nDespite its skyrocketing sales and its relative freedom from the expense of a significant advertising budget, Tattooed Chef still registered a net loss in Q1 2021. The company's bottom line has worsened year over year: It produced positive $5.9 million net income in Q1 2020 versus a $7.9 million net loss in the same period this year. It has seen a rise in operating expenses, including a few million directed towards marketing and several million directed towards stock compensation.\nWhile Tattooed Chef makes plant-based cauliflower burgers, it simply doesn't have the serious research and development (R&D) muscle of Beyond Meat or privately held Impossible Foods to produce meat substitutes at the same level. While Beyond and Impossible maintain laboratories and fund teams of scientists to develop plant protein faux meat closely mimicking the flavor, texture, cooking characteristics, nutrition, and even bleeding of actual meat and are working on similarly advanced plant-based milk and eggs, Tattooed Chef's cauliflower burgers are just spiced and breaded cauliflower patties, a far more casual approach.\nGiven that Beyond and Impossible owe their success to the accurate simulation of meat in a plant-based format, Tattooed Chef seems unlikely to tap strongly into that growth market. Its acai bowls, smoothie bowls, and other products, while proving salable, don't have the cutting-edge sales leverage of the advanced faux meats offered by its competitors and might be readily substituted with other companies' frozen meal bowls. Tattooed Chef, at this point, appears to lack the powerful, clear-cut product differentiation at the heart of the success of manufacturers like Beyond Meat.\n3. The high short interest in Tattooed Chef is a wild card\nOne factor with potentially unpredictable consequences for Tattooed Chef is high short interest, standing at slightly over 36% at the start of June. Under ordinary market conditions, this would be a negative, indicating a large cohort of short-sellers have done their due diligence and found the company's fundamentals to be significantly lacking. A few years ago, this beefy short interest would have been a definitive warning sign about the company's future.\nIn today's stock market climate, however, the high short interest could potentially attract the attention of large numbers of retail investors, such as those from the millions-strong r/WallStreetBets Reddit community. Noted for their tremendous short squeeze on the stock of video game seller GameStop and a growing handful of other \"meme stocks,\" these Redditors and other small investors remain on the lookout for heavily shorted stocks to buy in quantity.\nWhile Tattooed Chef seems to have drawn relatively little notice from these investors up until now, the quest for the next short squeeze takedown could eventually see the company become a meme stock, too. In this case, an attempted squeeze by WallStreetBets readers could pump immense streams of cash into Tattooed Chef, giving the company ample liquidity to aggressively pursue expansion, boost production capacity, and increase the range of product development.\nShould you add a taste of Tattooed Chef to your portfolio?\nWhile Tattooed Chef isn't making the groundbreaking plant-based meat or dairy products of Beyond Meat or Impossible Foods, it appears to have some real potential to become a profitable midsize vegetarian and vegan meal company. Its troubled bottom line and high short interest point to some risk, though, as noted, the latter could become an asset if the company becomes a meme stock and draws a major short squeeze cash inflow from Reddit retail investors at some point.\nEven without such a windfall, however, Tattooed Chef's entry into the Mexican-style food market, along with its rapid development of distribution channels, look like bullish indicators. While the company's future is uncertain and carries some risk, Fools investing in food stocks may want to consider adding at least a few of the company's shares to their holdings.","news_type":1},"isVote":1,"tweetType":1,"viewCount":597,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128808033,"gmtCreate":1624508774722,"gmtModify":1703838772002,"author":{"id":"3582358356914075","authorId":"3582358356914075","name":"hongweiiewgn","avatar":"https://static.tigerbbs.com/2f1848f0d6e2963f698914aeff51448e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582358356914075","authorIdStr":"3582358356914075"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128808033","repostId":"1182818110","repostType":4,"repost":{"id":"1182818110","pubTimestamp":1624504323,"share":"https://ttm.financial/m/news/1182818110?lang=&edition=fundamental","pubTime":"2021-06-24 11:12","market":"us","language":"en","title":"This Bull Is Far From Over: 3 Undervalued Blue Chip Dividend Buys","url":"https://stock-news.laohu8.com/highlight/detail?id=1182818110","media":"seekingalpha","summary":"Summary\n\nThe Fed jolted investors last week, before Powell backpedalled to reassure everyone.\nThis s","content":"<p><b>Summary</b></p>\n<ul>\n <li>The Fed jolted investors last week, before Powell backpedalled to reassure everyone.</li>\n <li>This shows just how difficult it will be for the Fed to actually rein in the economy.</li>\n <li>Some value names are once again on our \"buy list\". Here are three great ones.</li>\n</ul>\n<p><b>Introduction</b></p>\n<p>On a recent Bloomberg video call, Ray Dalio suggested that the Fed will have a lot of trouble doing any rate hike without having significantly adverse effects on stocks.</p>\n<p>Following the Fed meeting last week, the news that rates might be raised in two years rather than three gave the markets a jolt, as the message was interpreted as hawkish by the investing community.</p>\n<p>This caused Jerome Powell to backpedal, reminding everyone of his favorite word: \"transitory\". It was important that he once again reminded everyone that inflation would head back to 2%, and that nobody needs to worry.</p>\n<p>He did cover his 6 however,stating:</p>\n<blockquote>\n <i>We have to be very humble about our ability to really try to draw a signal out of it [...] It might take some patience to really see what’s happening.</i>\n</blockquote>\n<blockquote>\n Larry Summers had adifferent take on it: \n <i>I don't think the arithmetic is terribly difficult.</i>\n</blockquote>\n<blockquote>\n <i> You're looking at an average GDP gap deficit to potential GDP of 2%, and we're looking at a 14% of GDP fiscal stimulus. [...] The important question is whether there is 6 points of transitory inflation or 2 points of transitory inflation.</i>\n</blockquote>\n<p>This idea is very important. Rather than asking whether inflation is transitory or not, we should be asking how much of it is transitory.</p>\n<p>And this is where the risk currently lies. While the S&amp;P 500 (SPY) performed a roundtrip from 4250 to 4250 with a 90 point drop in between, a lot of the more cyclical stocks took a hit which put them back in our \"Buy List\".</p>\n<p>Our take is that the Fed is realizing that it can't really increase rates without causing ruckus in markets.</p>\n<p>When you add this to the fact that they might not have any choice but to keep printing money to buy bonds as the supply of bonds might overshoot the demand of these from foreign countries who already hold lots of US debt and show limited interest in purchasing the debt at negative real interest rates. This is according to Ray Dalio in the same call with Larry Summers mentioned above.</p>\n<p>The risk of monetary inflation is very real. The likelihood of demand to continue increasing dramatically as money stored in financial markets hits the economy is also very high.</p>\n<p>What we've learned in investing, is that investors are too eager to wrap up a trade and move on to the \"next thing\". Many times, this is shortsighted, as even when the train has left the station, there is a lot of track left ahead.</p>\n<p>This is one of these situations.</p>\n<p>Valuations in high quality blue chips which are sensitive to the economy reopening are still so far from pre-Covid levels.</p>\n<p>The fact that they are taking a breather doesn't detract from their ultimate destination, which is a lot higher.</p>\n<p>In this article I highlight 3 such stocks.</p>\n<p>Plus in the meantime you get to sleep well at night, knowing that they offer a great combination of dividend yield and dividend growth.</p>\n<p>Heads you win, tails you win more.</p>\n<p><b>IBM (IBM)</b></p>\n<p>While IBM has increased from our latest mention of it in a public article, when we were purchasing the stock at a 5%+ yield, it still hovers just below our target \"Buy Below\" price of $150, courtesy of a small pull back last week.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1a8abbcb78d88ebe9b82eb258078cd4c\" tg-width=\"640\" tg-height=\"297\" referrerpolicy=\"no-referrer\"><span>Source: Dividend Freedom Tribe.</span></p>\n<p>Dividend growth has come to a stand still, and while we loaded up lower, it is still a great opportunity.</p>\n<p>The real value lies in the fact that investors are not pricing Krishna's operational excellence since taking over.</p>\n<p>IBM stunned investors with its Q1 results. Fellow author Virginia Backaitis states in her excellent articleanalyzing IBM'soperations:</p>\n<blockquote>\n <i>I like how Krishna is thinking, and I like former Red Hat CEO Jim Whitehurst at his side. They are making purchases that align with IBM's strategy which hasn't always been the case at the company. The product lines that IBM is selling off now are smart choices... and they have others left to sell (but maybe there isn't a buyer).</i>\n</blockquote>\n<p>This value will likely be realized following the spin-off of the legacy business into an entity which will benamed kyndryl.</p>\n<p>Investors will likely be left with a high yield managed infrastructure business, and a low yield high growth cloud stock.</p>\n<p>When it happens, we'll decide which of both we'll hold onto, but we're quite confident that the two pieces will be worth than the sum of the part.</p>\n<p>And while you wait for this, you still get paid 4.5% by a super safe Blue Chip stock, which has the pricing power to fight inflation.</p>\n<p><b>KeyCorp (KEY)</b></p>\n<p>One thing the last round of stress tests showed, was that US banks are resilient, and well capitalized. Yet last week they took a hit after the fed meeting. This week stress tests will be released, and most large banks are expected to do really well.</p>\n<p>After that, dividend increases will come in July as banks are eager to start returning wealth to shareholders.</p>\n<p>Keycorp is no exception. For an analysis of KEY's earnings development you can read Sheen Bay Research'sarticleon the stock.</p>\n<p>Where I differ from his opinion is on the question of the dividend. While he doesn't expect a dividend hike, I expect all major banks to compete in their dividend increases.</p>\n<p>What investors must not forget is that in 2008 KEY paid a dividend of $0.38 per quarter, or double the current dividend.</p>\n<p>Since then, the company has been slowly redeeming itself, increasing the dividend every year.</p>\n<p>The pandemic restrictions stopped KEY in their tracks.</p>\n<p>A look at our MAD Chart shows how eager the bank was at returning capital to shareholders in the past 10 years. Each time the dividend increases, the inferred value ranges shown on the MAD chart goes up.</p>\n<p>In the past 10 years the dividend grew at 20% per annum, the rate dropped to 15% in the past 5 years, hindered by 0 growth last year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ce032ffe59e73db2d6a1e09b4ff723b4\" tg-width=\"640\" tg-height=\"298\" referrerpolicy=\"no-referrer\"><span>Source: Dividend Freedom Tribe.</span></p>\n<p>I believe that a 10-15% increase is very likely this year.</p>\n<p>In this event, KEY's current yield of 3.6% would effectively become a 4% yield.</p>\n<p>But to get fantastic income from KEY, you don't even need that much growth.</p>\n<p>At a 3.6% yield, if you can get 7.5% annual dividend growth you get a fantastic income opportunity.</p>\n<p>Let's look at a simulation.</p>\n<p>Let's suggest a $10K investment in KEY, with dividends reinvested and dividend growth of 7.5% per annum.</p>\n<p>In year 10, you'd expect $1,004 of income, or 10% of your original investment, which is our threshold for a \"great\" income opportunity.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/96c24e62697eb475528e1b9f04686a12\" tg-width=\"615\" tg-height=\"240\" referrerpolicy=\"no-referrer\"><span>Source: Dividend Freedom Tribe.</span></p>\n<p>In our mind there is no way that KEY doesn't grow at this rate, which would suggest hitting its pre 2008 dividend in 10 years.</p>\n<p>As such we believe KEY to be a great pick for income investors. As KEY's dividend growth is on the back of growth in earnings and tangible book value per share, there is no doubt in our mind that sooner or later, the price will catch up with the higher income. The fed stress tests might be the catalyst banks need to move higher.</p>\n<p>In the meantime get paid to wait.</p>\n<p><b>Chevron (CVX)</b></p>\n<p>Chevron is another stock which is hovering just below our target \"Buy Below\" price.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/100902df9308eeb7576e22704f403240\" tg-width=\"640\" tg-height=\"298\" referrerpolicy=\"no-referrer\"><span>Source: Dividend Freedom Tribe.</span></p>\n<p>We're surprised that the oil trade is taking so long to play out. In late 2015, early 2016, the recovery to historically normal yields was a lot faster.</p>\n<p>Yet CVX still yields 5%, after proving its resilience, superior balance sheet and increasing the dividend by 4% this year, sustaining their history of higher dividends every year for the past three decades.</p>\n<p>Consider the following slide from their latestearnings call:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b49cefbd9ee55c299d2b3a03211a3b6b\" tg-width=\"640\" tg-height=\"360\" referrerpolicy=\"no-referrer\"><span>Source: Earnings Call.</span></p>\n<p>At $40 brent, the dividend is covered with a little extra debt. As the energy major with the best balance sheet, it can afford this. At $60 brent, there would be excess cash above $25bn, or enough to fund the dividend for two and a half years.</p>\n<p>Brent is currently above $70. The longer it stays above that level, the higher the likelihood that CVX will actually have the excess cash suggested in the latter scenario.</p>\n<p>Back in August last year we suggested that you'll belaughing your wayto the bank with CVX's 6% yield.</p>\n<p>Since then, CVX has marginally beaten the S&amp;P 500, but is far from over.</p>\n<p>In the past 10 years CVX has yielded a median 3.86%. Its forward outlook is arguably better now than it was in much of the past decade, which had the energy market dealing with endemic oversupply. With underinvestment, the opposite is likely to be true in upcoming years.</p>\n<p>If anything CVX should gravitate back towards its median yield which suggests further upside of 20%, much of which we expect will be realized in the latter half of 2021.</p>\n<p>If you simulate a $10K investment in CVX assuming a 5% yield and 4% dividend growth, and reinvest dividends, then in year 10 you'd expect $1,154 in dividends of which $409 is expected to come from dividend reinvestments.</p>\n<p>This equates to 11.54% of the initial investment, making CVX also an excellent income opportunity at current prices.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/53e365890df23b4af31565c7b170c14f\" tg-width=\"615\" tg-height=\"240\" referrerpolicy=\"no-referrer\"><span>Source: Dividend Freedom Tribe.</span></p>\n<p><b>Conclusion</b></p>\n<p>As long term dividend investors, we're always eager to get top companies at great valuations. The fed meeting changed nothing to the reopening trade. If anything it gave them a warning that even the slightest hint of a rate increase would be interpreted as hawkish, which will likely have the consequence of them acting later than they should, which exacerbates the likelihood of the value trade continuing.</p>\n<p>Don't confuse the market taking a breather with the end of the trade.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Bull Is Far From Over: 3 Undervalued Blue Chip Dividend Buys</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Bull Is Far From Over: 3 Undervalued Blue Chip Dividend Buys\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 11:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4436276-this-bull-is-far-from-over-3-undervalued-blue-chip-dividend-buys><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nThe Fed jolted investors last week, before Powell backpedalled to reassure everyone.\nThis shows just how difficult it will be for the Fed to actually rein in the economy.\nSome value names are...</p>\n\n<a href=\"https://seekingalpha.com/article/4436276-this-bull-is-far-from-over-3-undervalued-blue-chip-dividend-buys\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVX":"雪佛龙","IBM":"IBM","KEY":"KeyCorp"},"source_url":"https://seekingalpha.com/article/4436276-this-bull-is-far-from-over-3-undervalued-blue-chip-dividend-buys","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1182818110","content_text":"Summary\n\nThe Fed jolted investors last week, before Powell backpedalled to reassure everyone.\nThis shows just how difficult it will be for the Fed to actually rein in the economy.\nSome value names are once again on our \"buy list\". Here are three great ones.\n\nIntroduction\nOn a recent Bloomberg video call, Ray Dalio suggested that the Fed will have a lot of trouble doing any rate hike without having significantly adverse effects on stocks.\nFollowing the Fed meeting last week, the news that rates might be raised in two years rather than three gave the markets a jolt, as the message was interpreted as hawkish by the investing community.\nThis caused Jerome Powell to backpedal, reminding everyone of his favorite word: \"transitory\". It was important that he once again reminded everyone that inflation would head back to 2%, and that nobody needs to worry.\nHe did cover his 6 however,stating:\n\nWe have to be very humble about our ability to really try to draw a signal out of it [...] It might take some patience to really see what’s happening.\n\n\n Larry Summers had adifferent take on it: \n I don't think the arithmetic is terribly difficult.\n\n\n You're looking at an average GDP gap deficit to potential GDP of 2%, and we're looking at a 14% of GDP fiscal stimulus. [...] The important question is whether there is 6 points of transitory inflation or 2 points of transitory inflation.\n\nThis idea is very important. Rather than asking whether inflation is transitory or not, we should be asking how much of it is transitory.\nAnd this is where the risk currently lies. While the S&P 500 (SPY) performed a roundtrip from 4250 to 4250 with a 90 point drop in between, a lot of the more cyclical stocks took a hit which put them back in our \"Buy List\".\nOur take is that the Fed is realizing that it can't really increase rates without causing ruckus in markets.\nWhen you add this to the fact that they might not have any choice but to keep printing money to buy bonds as the supply of bonds might overshoot the demand of these from foreign countries who already hold lots of US debt and show limited interest in purchasing the debt at negative real interest rates. This is according to Ray Dalio in the same call with Larry Summers mentioned above.\nThe risk of monetary inflation is very real. The likelihood of demand to continue increasing dramatically as money stored in financial markets hits the economy is also very high.\nWhat we've learned in investing, is that investors are too eager to wrap up a trade and move on to the \"next thing\". Many times, this is shortsighted, as even when the train has left the station, there is a lot of track left ahead.\nThis is one of these situations.\nValuations in high quality blue chips which are sensitive to the economy reopening are still so far from pre-Covid levels.\nThe fact that they are taking a breather doesn't detract from their ultimate destination, which is a lot higher.\nIn this article I highlight 3 such stocks.\nPlus in the meantime you get to sleep well at night, knowing that they offer a great combination of dividend yield and dividend growth.\nHeads you win, tails you win more.\nIBM (IBM)\nWhile IBM has increased from our latest mention of it in a public article, when we were purchasing the stock at a 5%+ yield, it still hovers just below our target \"Buy Below\" price of $150, courtesy of a small pull back last week.\nSource: Dividend Freedom Tribe.\nDividend growth has come to a stand still, and while we loaded up lower, it is still a great opportunity.\nThe real value lies in the fact that investors are not pricing Krishna's operational excellence since taking over.\nIBM stunned investors with its Q1 results. Fellow author Virginia Backaitis states in her excellent articleanalyzing IBM'soperations:\n\nI like how Krishna is thinking, and I like former Red Hat CEO Jim Whitehurst at his side. They are making purchases that align with IBM's strategy which hasn't always been the case at the company. The product lines that IBM is selling off now are smart choices... and they have others left to sell (but maybe there isn't a buyer).\n\nThis value will likely be realized following the spin-off of the legacy business into an entity which will benamed kyndryl.\nInvestors will likely be left with a high yield managed infrastructure business, and a low yield high growth cloud stock.\nWhen it happens, we'll decide which of both we'll hold onto, but we're quite confident that the two pieces will be worth than the sum of the part.\nAnd while you wait for this, you still get paid 4.5% by a super safe Blue Chip stock, which has the pricing power to fight inflation.\nKeyCorp (KEY)\nOne thing the last round of stress tests showed, was that US banks are resilient, and well capitalized. Yet last week they took a hit after the fed meeting. This week stress tests will be released, and most large banks are expected to do really well.\nAfter that, dividend increases will come in July as banks are eager to start returning wealth to shareholders.\nKeycorp is no exception. For an analysis of KEY's earnings development you can read Sheen Bay Research'sarticleon the stock.\nWhere I differ from his opinion is on the question of the dividend. While he doesn't expect a dividend hike, I expect all major banks to compete in their dividend increases.\nWhat investors must not forget is that in 2008 KEY paid a dividend of $0.38 per quarter, or double the current dividend.\nSince then, the company has been slowly redeeming itself, increasing the dividend every year.\nThe pandemic restrictions stopped KEY in their tracks.\nA look at our MAD Chart shows how eager the bank was at returning capital to shareholders in the past 10 years. Each time the dividend increases, the inferred value ranges shown on the MAD chart goes up.\nIn the past 10 years the dividend grew at 20% per annum, the rate dropped to 15% in the past 5 years, hindered by 0 growth last year.\nSource: Dividend Freedom Tribe.\nI believe that a 10-15% increase is very likely this year.\nIn this event, KEY's current yield of 3.6% would effectively become a 4% yield.\nBut to get fantastic income from KEY, you don't even need that much growth.\nAt a 3.6% yield, if you can get 7.5% annual dividend growth you get a fantastic income opportunity.\nLet's look at a simulation.\nLet's suggest a $10K investment in KEY, with dividends reinvested and dividend growth of 7.5% per annum.\nIn year 10, you'd expect $1,004 of income, or 10% of your original investment, which is our threshold for a \"great\" income opportunity.\nSource: Dividend Freedom Tribe.\nIn our mind there is no way that KEY doesn't grow at this rate, which would suggest hitting its pre 2008 dividend in 10 years.\nAs such we believe KEY to be a great pick for income investors. As KEY's dividend growth is on the back of growth in earnings and tangible book value per share, there is no doubt in our mind that sooner or later, the price will catch up with the higher income. The fed stress tests might be the catalyst banks need to move higher.\nIn the meantime get paid to wait.\nChevron (CVX)\nChevron is another stock which is hovering just below our target \"Buy Below\" price.\nSource: Dividend Freedom Tribe.\nWe're surprised that the oil trade is taking so long to play out. In late 2015, early 2016, the recovery to historically normal yields was a lot faster.\nYet CVX still yields 5%, after proving its resilience, superior balance sheet and increasing the dividend by 4% this year, sustaining their history of higher dividends every year for the past three decades.\nConsider the following slide from their latestearnings call:\nSource: Earnings Call.\nAt $40 brent, the dividend is covered with a little extra debt. As the energy major with the best balance sheet, it can afford this. At $60 brent, there would be excess cash above $25bn, or enough to fund the dividend for two and a half years.\nBrent is currently above $70. The longer it stays above that level, the higher the likelihood that CVX will actually have the excess cash suggested in the latter scenario.\nBack in August last year we suggested that you'll belaughing your wayto the bank with CVX's 6% yield.\nSince then, CVX has marginally beaten the S&P 500, but is far from over.\nIn the past 10 years CVX has yielded a median 3.86%. Its forward outlook is arguably better now than it was in much of the past decade, which had the energy market dealing with endemic oversupply. With underinvestment, the opposite is likely to be true in upcoming years.\nIf anything CVX should gravitate back towards its median yield which suggests further upside of 20%, much of which we expect will be realized in the latter half of 2021.\nIf you simulate a $10K investment in CVX assuming a 5% yield and 4% dividend growth, and reinvest dividends, then in year 10 you'd expect $1,154 in dividends of which $409 is expected to come from dividend reinvestments.\nThis equates to 11.54% of the initial investment, making CVX also an excellent income opportunity at current prices.\nSource: Dividend Freedom Tribe.\nConclusion\nAs long term dividend investors, we're always eager to get top companies at great valuations. The fed meeting changed nothing to the reopening trade. If anything it gave them a warning that even the slightest hint of a rate increase would be interpreted as hawkish, which will likely have the consequence of them acting later than they should, which exacerbates the likelihood of the value trade continuing.\nDon't confuse the market taking a breather with the end of the trade.","news_type":1},"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}